美国Proteintech Group，Inc. www.ptglab.com
PROTEINTECH GROUP，INC.于2001年在美国芝加哥成立，是一家以开发、生产、销售抗体/重组蛋白及相关产品为主要业务的生物技术公司。同年在中国成立全资子公司武汉三鹰生物技术有限公司，2006年在英国曼彻斯特成立欧洲分公司Proteintech Europe,LTD。
PROTEINTECH GROUP作为一家拥有独立品牌的抗体公司，自公司成立以来，致力于开发针对所有人类蛋白的抗体—人类抗体组计划，迄今已生产出针对10,000种不同人类蛋白的10,000余种抗体，涵盖了生命科学的各个研究领域。产品被发表在各大学术期刊的论文频繁引用，在国际学术界建立了独具特色的品牌和牢固的地位，是本领域内近年出现的佼佼者。
PROTEINTECH GROUP 作为全球最大的抗体生产商之一，拥有一支锐意进取的技术研发团队和成熟稳定的技术平台，每周都有新产品推出，信息在网站上实时更新，检测数据日益完善。并且在全球建立了市场销售网络，美国，欧洲，中国和日本都建有库存，可以做到24小时现货发售，快捷方便！
PROTEINTECH GROUP致力于向全球客户提供高质量的抗体以及相关的制备抗体服务，逐步扩大产品种类和范围，力争成为生物技术领域最优秀的产品供应商和生命科学工作者可信赖的朋友。我们坚信：您的成功就是我们的成功！

The mission of Proteintech Group, Inc is to develop, manufacture a wide spectrum of antibodies against all human proteins known as Human Antibody Projects, thus providing the most effective tools for the identification and quantization of the vast number of known or unknown disease markers. Our philosophy is to be a part of the solution of the research community by providing scientists with every possible antibody they will need and at a reasonable cost. As all founders of the company are bench-side researchers, we have the deepest appreciation for the highest standard of perfection that all scientists hold for their projects, and therefore we hold our products to the same standard. As a part of this research community, we firmly committed to be a silent partner of every research laboratory and every research project.

Therefore it is the responsibility of Proteintech Group to offer researches with a variety of antibodies and related products at highest quality as possible so that the researchers can focus on their creativity, skill and effort as well as funding, without ever having to concern with the quality of reagents used. We also committed to provide them at lowest possible cost because we understand that every dollar of the research grant is the result of hard work of the researchers. Every dollar we saved is a dollar they have earned.

As the silent partner in your research career, you can count on us to solve your supply and technical needs on antibodies and antibody related products. We deeply understand that only if you succeed, we will succeed.

Our Promise:

Proteintech Group offers a variety of polyclonal and monoclonal antibodies for your research. Each antibody is thoroughly tested for its ability to perform immunoprecipitation, immunoblotting and immunohistochemistry so that you can be confident in using them. Understanding each antibody has its unique applications and features, we also provide our customers with complete technical support and detailed instructions for each application. To maximize your research flexibility, we promise following services.

For Investors:

The antibody and antibody-related products for research, biotech and clinical diagnostics constitute huge but unsaturated market in the world, and it is subject to a high growth trend. In the US, the National Institute of Health alone receives 17 billion dollars federal funding, among that, 1.7 billion, i.e. 10% is spent on antibody and related reagents. Many private pharmaceutical companies spent many fold more on antibodies and its related products. Another growing market is the proteomic project (project to identify, profile all human proteins and their function), especially in the post genomic project period. Antibodies are the only type of reagents today to solve most problems in the Human Proteomic Project. It is estimated that some 300,000 different anti-human protein antibodies will be needed while there are only 10,000 Antigen specificities are available.

The mission of the Proteintech Group is to design, develop, and market antibody and antibody-chips in the Bioresearch field. The antibody will fill current market that accounts for a minimum of $ 1.7 billion dollars in potential sales. Each product shall be priced to appeal to researchers that stresses lowest cost and convenient.

The procedure of production and marketing has been tested. Projections from studies have shown that with a 2 million dollar initial investment, the company would expect $24 million in sales in year three with a net profit of approximately $20 million. The company would expect to have $38 million in revenue by year five. The company would be self sustained in year one and will be able to break even between year one and two, purely based on antibody production and sales.

in next five years, the estimated market of products yielded from proteomic project would reach to 40 billion. The Proteintech Group is currently developing antibody chips (a collection of thousand antibodies arranged in arrays for quick identification and quantitation of known or unknown proteins in a mixture, such as in blood), a key product of this market. With its advantages of its massive antibody production, the proposed company would gain an edge in the production of antibody chips.